Shingrix, a shingles vaccine, will be released in December

What's different from the competition

The existing two vaccines have a 51% prevention rate for those over 50 years of age

Shingrix is 97%

It's the only anti-vaccine vaccine, and even immunocompromised...Proof of long-term effectiveness and safety

Shingrix, a new shingles vaccine that boasts overwhelming preventive effects, will be officially released in December.

 

It is expected to shake the game of shingles vaccines by showing a 97% prevention effect, which is twice that of existing vaccines, and proving long-term effectiveness and safety.

 

On the other hand, prices are more than four times higher and small initial supplies are considered barriers.

 

According to the pharmaceutical industry on the 17th, GSK will release a new shingles vaccine, Shingrix, in Korea in December.

 

It has been a year and three months since it was approved by the Ministry of Food and Drug Safety in Korea.

 

Shingrix is an antigen of Glycoprotein E, a protein component of chickenpox and shingles virus.

 

It combines AS01B, an immune enhancer that improves the immune response to the antigen, to exhibit a strong and continuous immune response.

 

Shingrix is the third shingles vaccine and the first vaccine in Korea.

 

Previously, it was a two-tier system of SKY Zoster by MSD Zostavax and SK Bioscience.

 

Both products are live vaccines, which transformed parts of viruses or bacteria, eliminating the ability to produce toxicity, and leaving only self-breeding and immune-inducing capabilities.

 

On the other hand, Shingrix, a four-vaccine vaccine, is a special treatment that deactivates all or part of a virus or bacteria and can be inoculated even to those who have difficulty getting a live vaccine due to reduced immunity.

 

◆The prevention rate of herpes zoster among those in their 50s and older is 97% The biggest advantage of Shingrix is by far the prevention rate.

 

Unlike Zostavax and SKY Zoster, which showed a 51% prevention effect in patients over the age of 50, Shingrix had a 97% prevention rate.

 

According to Shingrix Phase III clinical trial ZOE-50, Shingrix has a 97.2% preventive effect over an average 3.2-year follow-up period.

 

In the results of separately selecting and analyzing ZOE-70 clinical trials and participants in the ZEO-50 study for patients aged 70 or older, Singrix maintained a preventive effect of more than 90%.

 

Specifically, Shingrix had a 91% prevention rate in both 70s and 80s.

 

This is in contrast to existing vaccines, which have fallen to 41% of the prevention effect among those aged 70 and older.

 

Even if you have shingles after vaccination with Shingrix, the probability of preventing "shingles post-shingles neuralgia," a representative complication, was 91% for those over the age of 50 and 89% for those over the age of 70.

 

The long-term effects of Shingrix are also being demonstrated.

 

Currently, GSK is conducting a long-term follow-up study on clinical participants to see the long-term safety and effectiveness of Shingrix.

 

According to the current confirmation, 91% of preventive effects were maintained for 7.1 years after Shingrix vaccination in all age groups over the age of 50.

 

While maintaining a stable response to immunogenicity and cell-mediated immunity, the antibody concentration was found to be more than six times higher than the level before vaccination until eight years after vaccination.

 

◆ Two inoculations and expensive price barriers…The disadvantage is that 180,000 units are small In addition to the preventive effect, Shingrix differs from existing vaccines in terms of the number of vaccinations and price.

 

Unlike Zostavax and SKY Zoster, which are one inoculation, Shingrix is two inoculations.

 

You should get another vaccine between 2 and 6 months after the first vaccination.

 

The cost of vaccination is expected to be 4 to 5 times higher than that of existing vaccines.

 

According to the industry, GSK recently set the supply price of Shingrix at around 160,000 won per dose.

 

The inoculation price, which reflects the supply price, is expected to be around 300,000 won.

 

Considering that it is a total of two vaccinations, the total vaccination price that the patient has to pay is around 600,000 won.

 

Currently, the inoculation price of Zostavax and SKY Zoster is about 150,000 won to 200,000 won.

 

In other words, it becomes as expensive as four times at least, and five times at most.

 

Despite the high inoculation price, Shingrix is expected to change the market landscape due to its unique preventive effect.

 

The U.S.

 

has already been overturned as a soloist, accounting for 98% of the market share within a year of its launch.

 

Shingrix's U.S.

 

sales reached 2.5 trillion won in 2019 and about 3 trillion won in 2020.

 

Sales fell last year when COVID-19 was severe, but the company predicted a more significant rebound this year However, it is expected that it will be difficult to meet Shingrix in front-line hospitals and clinics immediately after its launch in December due to insufficient initial supplies.

 

According to the industry, the initial volume of Shingrix is 360,000 doses, which can only fit 180,000 people.

 

The initial volume will also be introduced sequentially according to the domestic inspection schedule such as the national lot release, and the supply is expected to be supplied from general hospitals.